Kangmei Pharmaceutical's wholly-owned subsidiary, Tengwang Pavilion Pharmaceutical, needs to pay additional taxes and late fees totaling approximately 5.184 million yuan.

Kangmei Pharmaceutical Co., Ltd. (Stock Code: 600518, Stock Abbreviation: Kangmei Pharmaceutical) recently announced that its wholly-owned subsidiary Kangmei Tengwang Pavilion (Sichuan) Pharmaceutical Co., Ltd. (hereinafter referred to as “Tengwang Pavilion Pharmaceutical”) received a “Tax Treatment Decision” issued by the Third Inspection Bureau of the Nanchong City Taxation Bureau of the State Administration of Taxation, requiring the payment of 4.136 million yuan in corporate income tax for the years 2020 to 2024, along with the corresponding late fees.

The announcement indicates that, as determined by the tax authorities, the amount of corporate income tax that Tengwang Pavilion Pharmaceutical needs to pay is 4.136 million yuan, and late fees must also be paid. The above amounts must be paid within 15 days from the receipt of the “Tax Treatment Decision” and accounting adjustments must be made in accordance with regulations. This matter only involves the repayment of taxes and late fees and does not involve any tax administrative penalties.

Regarding the impact on the company, Kangmei Pharmaceutical stated that according to the relevant provisions of “Enterprise Accounting Standard No. 28 - Changes in Accounting Policies, Accounting Estimates, and Correction of Errors,” this repayment of taxes and late fees does not constitute a prior accounting error and does not involve retrospective adjustments to prior financial data. It is expected that this matter will affect the net profit attributable to shareholders of the listed company by approximately 5.184 million yuan in 2025, with the final data subject to the audited financial statements for 2025. The company also emphasized that this tax repayment matter will not affect the normal production and operation of the company.

Click to view the original announcement>>

Disclaimer: The market has risks, and investment should be cautious. This article is automatically published by an AI large model based on third-party databases and does not represent the views of Sina Finance. Any information appearing in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for discrepancies. For inquiries, please contact biz@staff.sina.com.cn.

Massive information, precise interpretation, all in the Sina Finance APP

Editor: Xiaolang Quick Report